MET and ovarian carcinoma: It has been reported that MET inhibition in osteosarcoma cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy [42], and overexpression of MET enhances survival of ovarian cancer cells and increased resistance to cisplatin [43].